Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
作者信息
Abu-Raddad Laith J, Chemaitelly Hiam, Butt Adeel A
机构信息
Weill Cornell Medicine-Qatar, Doha, Qatar
Hamad Medical Corporation, Doha, Qatar.
出版信息
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
Abstract
摘要
相似文献
1
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
2
Pfizer COVID vaccine protects against worrying coronavirus variants.
Nature. 2021 May;593(7859):325-326. doi: 10.1038/d41586-021-01222-5.
3
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
4
Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
Emerg Microbes Infect. 2021 Dec;10(1):1241-1243. doi: 10.1080/22221751.2021.1940305.
5
Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine in a Multicenter Cohort of Nursing Home Residents Receiving Maintenance Hemodialysis.
Am J Kidney Dis. 2021 Nov;78(5):766-768. doi: 10.1053/j.ajkd.2021.07.004. Epub 2021 Aug 6.
6
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.
Nat Med. 2021 Sep;27(9):1614-1621. doi: 10.1038/s41591-021-01446-y. Epub 2021 Jul 9.
7
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
8
Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
N Engl J Med. 2021 Sep 16;385(12):e48. doi: 10.1056/NEJMe2115200.
9
Audio Interview: Are Covid-19 Vaccine Boosters Necessary?
N Engl J Med. 2021 Oct 7;385(15):e63. doi: 10.1056/NEJMe2115835.
10
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lancet Respir Med. 2021 Sep;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4. Epub 2021 Jul 2.
引用本文的文献
1
ACE2 Receptor and Antibody Binding to SARS-CoV‑2 Spikes and Virions by Single-Molecule Fluorescence.
ACS Omega. 2025 Jul 31;10(31):34844-34856. doi: 10.1021/acsomega.5c03887. eCollection 2025 Aug 12.
2
Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study.
BMC Infect Dis. 2025 Aug 17;25(1):1028. doi: 10.1186/s12879-025-11410-7.
3
SARS-CoV-2 vaccines elicit differential Fc effector functions.
iScience. 2025 Jul 9;28(8):113084. doi: 10.1016/j.isci.2025.113084. eCollection 2025 Aug 15.
4
Membrane-wide screening identifies potential tissue-specific determinants of SARS-CoV-2 tropism.
PLoS Pathog. 2025 Jul 17;21(7):e1013157. doi: 10.1371/journal.ppat.1013157. eCollection 2025 Jul.
5
Immune histories and natural infection protection during the omicron era.
Commun Med (Lond). 2025 Jul 1;5(1):262. doi: 10.1038/s43856-025-00974-9.
6
Studying Disease Reinfection Rates, Vaccine Efficacy, and the Timing of Vaccine Rollout in the Context of Infectious Diseases: A COVID-19 Case Study.
Int J Environ Res Public Health. 2025 May 3;22(5):731. doi: 10.3390/ijerph22050731.
7
Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development.
Mol Ther Nucleic Acids. 2025 Mar 28;36(2):102527. doi: 10.1016/j.omtn.2025.102527. eCollection 2025 Jun 10.
8
Insight into the Role of the Aryl Hydrocarbon Receptor in Bovine Coronavirus Infection by an Integrated Approach Combining In Vitro and In Silico Methods.
Microorganisms. 2025 Mar 4;13(3):579. doi: 10.3390/microorganisms13030579.
9
An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants.
Pathogens. 2025 Jan 1;14(1):23. doi: 10.3390/pathogens14010023.
10
Protect or prevent? A practicable framework for the dilemmas of COVID-19 vaccine prioritization.
PLoS One. 2025 Jan 22;20(1):e0316294. doi: 10.1371/journal.pone.0316294. eCollection 2025.
Zotero 插件